Example collocations logo

Pharmaceutical in sentence

484 examples of Pharmaceutical in a sentence

I served on the Clinton administration’s Council of Economic Advisors at the time, and it was clear that there was more interest in pleasing the pharmaceutical and entertainment industries than in ensuring an intellectual-property regime that was good for science, let alone for developing countries.
This extraordinary feat was made possible by the Bill & Melinda Gates Foundation, and by pharmaceutical firms including Bayer, Novartis, Pfizer, and my company, Sanofi Pasteur.
The agreement gives pharmaceutical firms, tobacco companies, and other corporations substantially less than they had asked for – so much so that US Senator Orrin Hatch and some other Republicans now threaten to oppose ratification.
The left’s concerns about labor and the environment were accompanied by fears about excessive benefits for corporations: protection of the intellectual property of pharmaceutical and other companies, and the mechanisms used to settle disputes between investors and states.
The TPP’s critics often neglected to acknowledge that international dispute-settlement mechanisms could ever serve a valid purpose, or that some degree of patent protection is needed if pharmaceutical companies are to have sufficient incentive to invest in research and development.
Likewise, the intellectual property protections might have established a 12-year monopoly on the data that US pharmaceutical and biotechnology companies compile on new drugs (particularly biologics), thereby impeding competition from lower-cost generic versions.
The global health community has long appreciated the importance of a vaccine in reducing the disease’s burden, and the World Health Organization is expected to make an announcement in November about the use of Mosquirix in countries where malaria is endemic, some 30 excruciating years after researchers at the pharmaceutical company GlaxoSmithKline (GSK) began working on the vaccine.
GSK has said that Mosquirix will be offered “not for profit”; but the pharmaceutical company still must break even.
These include startups, IT companies that use local talent, organic-agro small and medium-size enterprises, export-oriented pharmaceutical companies, efforts to attract the international film industry to Greek locations, and educational programs that take advantage of Greek intellectual output and unrivaled historic sites.
And the British pharmaceutical giant GlaxoSmithKline, long positioned as a beacon of virtue in a sector known for its ethically dubious behavior, has been accused of bribery, tax fraud, price fixing, and improper research practices.
Quarterly earnings cycles, real-time pricing, and constant scrutiny by shareholders have pushed pharmaceutical companies toward projects with clear, immediate payoffs – at the expense of more speculative, but potentially transformational research.
Finally, there is the example of politicians like George W. Bush, who enacted a government program that promises comprehensive drug benefits to the elderly and mammoth profits to pharmaceutical companies.
America must also deal with the potential for corruption, both illegal in the case of the diversion of Teamsters’ pension resources and legal in the campaign contributions provided by the pharmaceutical lobby to complaisant members of Congress.
This requires more funding, which should come from the main beneficiary of drug sales – the pharmaceutical industry – just as oversight of aviation safety is funded by the airlines.
Venture capital has pulled back from early-stage life-sciences companies, and big pharmaceutical companies have seen fewer drugs reach the market per dollar spent on research and development.
Most are chasing the pharmaceutical and biotechnology industries.
For these countries, forming a megafund to test a few hundred compounds could be a much better bet than seeding biotech startups or offering incentives to big pharmaceutical firms.
Of course, getting governments to implement such measures will not be easy, because they run counter to powerful economic interests, the most obvious being the pharmaceutical industry, which sells $40 billion worth of antibiotics each year.
But the benefits of such incentives for pharmaceutical companies would far exceed the cost of the actual R&D pursued; they would be instruments to funnel public funds into private hands – the very hands that caused the problem.
I propose an initiative that rates pharmaceutical companies according to their contribution to solving the antibiotic-resistance problem; those that do not contribute should be punished with fewer sales.
At the World Economic Forum’s annual gathering in Davos last month, 85 companies, including vaccine developers, large pharmaceutical companies, diagnostic developers, and biotech firms, committed to further action to reduce drug resistance.
Nor are they subjected to the same rigorous toxicity studies as other pharmaceutical agents.
For example, US pharmaceutical companies have stronger intellectual-property protection at home than in the EU.
LONDON – Much attention has been focused in recent years on the pharmaceutical industry’s slowness to develop new drugs and lack of productivity.
But this crisis of innovation is also affecting the biotechnology firms upon which the large pharmaceutical companies now rely as the pipeline for developing new drugs.
Some propose abandoning the current system of patented drugs altogether and funding pharmaceutical R&D through taxation or prize-based systems.
Many large pharmaceutical companies are now espousing the virtue of these strategies, but will they work if adopted inconsistently by the industry and not at all by academia and funders?
Moreover, these benefits would be realized not only by pharmaceutical companies, but also by academics and other collaborators.
The advent of computing platforms such as Microsoft’s SharePoint have facilitated data-sharing and exchange, and pharmaceutical companies would do well to emulate companies from other sectors, such as Arup, which has developed excellent systems for accessing knowledge across its entire organization.
Some pharmaceutical companies like Lilly and Pfizer have demonstrated the power of this approach by implementing internal systems to seek solutions to problems organization-wide.
BackNext